Triple Negative Breast Cancer
Showing NaN - NaN of 34
Advanced Ovarian Cancer, Triple Negative Breast Cancer Trial in Worldwide (Atezolizumab, RO6870810)
Terminated
- Advanced Ovarian Cancer
- Triple Negative Breast Cancer
-
Boston, Massachusetts
- +10 more
Nov 5, 2020
Triple Negative Breast Cancer Trial in Worldwide (Tivozanib Hydrochloride, paclitaxel, Placebo)
Terminated
- Triple Negative Breast Cancer
- Tivozanib Hydrochloride
- +2 more
-
Birmingham, Alabama
- +53 more
Oct 5, 2020
Carcinoma, Renal Cell, Kidney Diseases, Kidney Tumors Trial in United States (Combination of Varlilumab and Atezolizumab)
Terminated
- Carcinoma, Renal Cell
- +13 more
- Combination of Varlilumab and Atezolizumab
-
San Francisco, California
- +3 more
Apr 26, 2018
Head and Neck Squamous Cell Carcinoma, NSCLC, Triple Negative Breast Cancer Trial in Boston, San Antonio, Madrid (ABBV-221)
Terminated
- Head and Neck Squamous Cell Carcinoma
- +4 more
-
Boston, Massachusetts
- +4 more
Mar 28, 2018
Breast Cancer, Triple Negative Breast Cancer, Stage IV Breast Cancer Trial in United States (Abraxane alone, Abraxane +
Completed
- Breast Cancer
- +3 more
- Abraxane alone
- Abraxane + Tigatuzumab
-
Birmingham, Alabama
- +9 more
Oct 24, 2017
Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast
Terminated
- Estrogen Receptor Negative Breast Cancer
- +5 more
- cisplatin
- +4 more
-
Birmingham, Alabama
- +15 more
May 22, 2017
